Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

 

Enter Stock Symbol:  

Celldex Therapeutics (CLDX)

0.66 0.003 (0.5%)

05-22 09:51

Open:

0.66

Pre. Close:

0.6567

High:

0.667

Low:

0.66

Volume:

474,633

Market Cap:

95M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

0.695 - 0.701

0.701 - 0.705

Low:

0.636 - 0.645

0.645 - 0.65

Close:

0.65 - 0.664

0.664 - 0.672

Technical analysis  (as of: 2018-05-21 4:27:46 PM)

Overall:

      

Stoxline posted a NEUTRAL today, same as yesterday. This stock seems to stay at current move trend, but it could change at anytime. So it is not a good time to buy or sell, stay at where you are until next Buy or SELL signal.

Target:

Six months: 0.93     One year: 1.03

Support:

Support1: 0.65    Support2: 0.54

Resistance:

Resistance1: 0.79    Resistance2: 0.88

Pivot:

0.74

Moving Averages:

MA(5): 0.69     MA(20): 0.74

MA(100): 2.07     MA(250): 2.42

MACD:

MACD(12,26): -0.21     Signal(12,26,9): -0.25

%K %D:

%K(14,3): 2.55     %D(3): 7.63

RSI:

RSI(14): 23.14

52-Week:

High: 3.26  Low: 0.65  Change(%): -78.7

Average Vol(K):

3-Month: 304245  10-Days 248122

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
CLDX has closed above bottom band by 5.2%. Bollinger Bands are 74% narrower than normal. The narrow width of the bands suggests low volatility as compared to CLDX's normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

2018-05-11T11:59:48-04:00
Celldex Trying To Regroup With Its Early-Stage Assets

2018-05-10T08:12:30-04:00
Celldex misses by $0.64, beats on revenue

2018-04-26T15:22:08-04:00
Biotech Analysis Central Pharma News: Takeda Raises Shire Bid, Daiichi Fails DMD Trial, Celldex Cuts 20% Of Workforce

2018-04-19T10:46:56-04:00
Celldex Nearly Back To Square One

2018-04-19T08:00:00-04:00
3 Things In Biotech, April 18: Bristol Plows Ahead, Celldex Flops, Alkermes Gets A Surprise

2018-04-18T13:54:41-04:00
OncoSec: The Underlying Science Of ImmunoPulse Powers A Potential Winner

2018-04-18T11:55:19-04:00
Celldex Tumbles On Phase 2 Trial Failure; Is There Any Value Left?

2018-04-17T02:29:11-04:00
Rounds Report: Regenxbio Surged Higher While Celldex Tumbled Due To A Negative Clinical Binary

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Biotechnology Medical Research

Shares Out. (M)

143.39

Shares Float (M)

136.77

% Held by Insiders

4.70

% Held by Institutions

49.90

Shares Short (K)

8112

Shares Short Prior Month (K)

7410

Stock Financials

EPS

-0.730

EPS Est. Current Year

-1.040

EPS Est. Next Year

-0.950

EPS Est. Next Quarter

-0.280

Forward EPS

-0.818

Book Value (p.s.)

0.440

PEG Ratio

Profit Margin

Operating Margin

-662.69

Return on Assets (ttm)

-26.6

Return on Equity (ttm)

-37.1

Qtrly Rev. Growth

165.2

Gross Profit (p.s.)

Sales Per Share

EBITDA (p.s.)

-0.407

Qtrly Earnings Growth

Operating Cash Flow (M)

-92.69

Levered Free Cash Flow (M)

-53.01

atoplab.com

Valuation

P/E

-0.90

P/E Growth Ratio

-0.02

P/BV

1.49

P/S

784701760.00

P/CF

-1.02

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.